News
Public · Published
Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
Sellas Life Sciences said it will present Phase 2 results for experimental blood cancer treatment SLS009 at next month's American Society of Hematology meeting. The reported study tested SLS009 with azacitidine and venetoclax in 62 patients with relapsed or treatment-resistant AML, and results for newly diagnosed patients are expected in Q4 2026.
Published:
Updated:
What happened
Sellas Life Sciences said it will present Phase 2 results for experimental blood cancer treatment SLS009 at next month’s American Society of Hematology meeting. The reported study tested SLS009 with azacitidine and venetoclax in 62 patients with relapsed or treatment-resistant AML, and results for newly diagnosed patients are expected in Q4 2026.
Confirmed
Global impact / market context
The reported response rates and survival figures may shape views of SLS009’s clinical promise, but the results concern patients whose AML had relapsed or resisted earlier treatment. If later studies confirm benefit in newly diagnosed patients, that could support broader use and strengthen Sellas’s ability to advance the program.
Analyst inference
The article reports a planned conference presentation and early-stage trial results, not an approval or established treatment benefit. For a biotech company, further clinical evidence can influence expectations about development costs and future revenue, while uncertain outcomes leave the program exposed to trial risk.
Analyst inference
What to watch
- Watch for the full conference presentation next month, including how investigators explain the 62-patient study and whether additional details clarify the reported response and survival results. Confirmed
- Initial results from Sellas’s 80-patient Phase 2 study in newly diagnosed AML are expected in Q4 2026; assess whether the findings support continued development. Confirmed
- Compare future results with the reported outcomes in relapsed disease; consistent benefit across patient groups could improve the case for investment, while weaker findings could reduce confidence. Analyst inference